Cargando…

Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents

Dipeptidyl peptidase-IV (DPP-IV) inhibitors, often known as gliptins, have been used to treat type 2 diabetes mellitus (T2DM). They may be combined with other medications as an additional treatment or used alone as a monotherapy. In addition to insulin, sulfonylureas, thiazolidinediones, and metform...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammad, Badrud Duza, Baig, Mirza Shahed, Bhandari, Neeraj, Siddiqui, Falak A., Khan, Sharuk L., Ahmad, Zubair, Khan, Farhat S., Tagde, Priti, Jeandet, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502781/
https://www.ncbi.nlm.nih.gov/pubmed/36144735
http://dx.doi.org/10.3390/molecules27186001
_version_ 1784795790331346944
author Mohammad, Badrud Duza
Baig, Mirza Shahed
Bhandari, Neeraj
Siddiqui, Falak A.
Khan, Sharuk L.
Ahmad, Zubair
Khan, Farhat S.
Tagde, Priti
Jeandet, Philippe
author_facet Mohammad, Badrud Duza
Baig, Mirza Shahed
Bhandari, Neeraj
Siddiqui, Falak A.
Khan, Sharuk L.
Ahmad, Zubair
Khan, Farhat S.
Tagde, Priti
Jeandet, Philippe
author_sort Mohammad, Badrud Duza
collection PubMed
description Dipeptidyl peptidase-IV (DPP-IV) inhibitors, often known as gliptins, have been used to treat type 2 diabetes mellitus (T2DM). They may be combined with other medications as an additional treatment or used alone as a monotherapy. In addition to insulin, sulfonylureas, thiazolidinediones, and metformin, these molecules appear as possible therapeutic options. Oxadiazole rings have been employed in numerous different ways during drug development efforts. It has been shown that including them in the pharmacophore increases the amount of ligand that may be bound. The exceptional hydrogen bond acceptor properties of oxadiazoles and the distinct hydrocarbon bonding potential of their regioisomers have been established. Beside their anti-diabetic effects, oxadiazoles display a wide range of pharmacological properties. In this study, we made the assumption that molecules containing oxadiazole rings may afford a different approach to the treatment of diabetes, not only for controlling glycemic levels but also for preventing atherosclerosis progression and other complications associated with diabetes. It was observed that oxadiazole fusion with benzothiazole, 5-(2,5,2-trifluoroethoxy) phenyl, β-homophenylalanine, 2-methyl-2-{5-(4-chlorophenyl), diamine-bridged bis-coumarinyl, 5-aryl-2-(6′-nitrobenzofuran-2′-yl), nitrobenzofuran, and/or oxindole leads to potential anti-diabetic activity.
format Online
Article
Text
id pubmed-9502781
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95027812022-09-24 Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents Mohammad, Badrud Duza Baig, Mirza Shahed Bhandari, Neeraj Siddiqui, Falak A. Khan, Sharuk L. Ahmad, Zubair Khan, Farhat S. Tagde, Priti Jeandet, Philippe Molecules Review Dipeptidyl peptidase-IV (DPP-IV) inhibitors, often known as gliptins, have been used to treat type 2 diabetes mellitus (T2DM). They may be combined with other medications as an additional treatment or used alone as a monotherapy. In addition to insulin, sulfonylureas, thiazolidinediones, and metformin, these molecules appear as possible therapeutic options. Oxadiazole rings have been employed in numerous different ways during drug development efforts. It has been shown that including them in the pharmacophore increases the amount of ligand that may be bound. The exceptional hydrogen bond acceptor properties of oxadiazoles and the distinct hydrocarbon bonding potential of their regioisomers have been established. Beside their anti-diabetic effects, oxadiazoles display a wide range of pharmacological properties. In this study, we made the assumption that molecules containing oxadiazole rings may afford a different approach to the treatment of diabetes, not only for controlling glycemic levels but also for preventing atherosclerosis progression and other complications associated with diabetes. It was observed that oxadiazole fusion with benzothiazole, 5-(2,5,2-trifluoroethoxy) phenyl, β-homophenylalanine, 2-methyl-2-{5-(4-chlorophenyl), diamine-bridged bis-coumarinyl, 5-aryl-2-(6′-nitrobenzofuran-2′-yl), nitrobenzofuran, and/or oxindole leads to potential anti-diabetic activity. MDPI 2022-09-15 /pmc/articles/PMC9502781/ /pubmed/36144735 http://dx.doi.org/10.3390/molecules27186001 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mohammad, Badrud Duza
Baig, Mirza Shahed
Bhandari, Neeraj
Siddiqui, Falak A.
Khan, Sharuk L.
Ahmad, Zubair
Khan, Farhat S.
Tagde, Priti
Jeandet, Philippe
Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents
title Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents
title_full Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents
title_fullStr Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents
title_full_unstemmed Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents
title_short Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents
title_sort heterocyclic compounds as dipeptidyl peptidase-iv inhibitors with special emphasis on oxadiazoles as potent anti-diabetic agents
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502781/
https://www.ncbi.nlm.nih.gov/pubmed/36144735
http://dx.doi.org/10.3390/molecules27186001
work_keys_str_mv AT mohammadbadrudduza heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents
AT baigmirzashahed heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents
AT bhandarineeraj heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents
AT siddiquifalaka heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents
AT khansharukl heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents
AT ahmadzubair heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents
AT khanfarhats heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents
AT tagdepriti heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents
AT jeandetphilippe heterocycliccompoundsasdipeptidylpeptidaseivinhibitorswithspecialemphasisonoxadiazolesaspotentantidiabeticagents